HOUSE OF REPRESENTATIVES THIRTY-SECOND LEGISLATURE, 2023 STATE OF HAWAII H.B. NO. ¹⁰⁸² H.D. 3 S.D. 2

A BILL FOR AN ACT

RELATING TO MEDICAL CANNABIS.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

SECTION 1. Section 329-121, Hawaii Revised Statutes, is
 amended by amending the definition of "written certification" to
 read as follows:

""Written certification" means the qualifying patient's 4 5 medical records or a statement signed by a gualifying patient's physician or advanced practice registered nurse, stating that in 6 7 the physician's or advanced practice registered nurse's 8 professional opinion, the qualifying patient has a debilitating 9 medical condition and the potential benefits of the medical use 10 of cannabis would likely outweigh the health risks for the 11 qualifying patient. The department of health may require, 12 through its rulemaking authority, that all written 13 certifications comply with a designated form. "Written 14 certifications" are valid for one year from the time of signing; 15 provided that the department of health may allow for the 16 validity of any written certification for [up to] three years if 17 the qualifying patient's physician or advanced practice

2023-2671 HB1082 SD2 SMA.docx



1 registered nurse states that the patient's debilitating medical 2 condition is chronic in nature."

3 SECTION 2. Section 329-123, Hawaii Revised Statutes, is
4 amended by amending subsection (a) to read as follows:

Physicians or advanced practice registered nurses who 5 "(a) 6 issue written certifications shall provide, in each written certification, the name, address, patient identification number, 7 and other identifying information of the qualifying patient. 8 9 The department of health shall require, in rules adopted 10 pursuant to chapter 91, that all written certifications comply 11 with a designated form completed by or on behalf of a qualifying 12 patient. The form shall require information from the applicant, 13 primary caregiver, and physician or advanced practice registered 14 nurse as specifically required or permitted by this chapter. 15 The form shall require the address of the location where the 16 cannabis is grown and shall appear on the registry card issued 17 by the department of health. The certifying physician or 18 advanced practice registered nurse shall be required to have a 19 [bona fide] physician-patient relationship or [bona fide] 20 advanced practice registered nurse-patient relationship, as 21 applicable, with the qualifying patient. All current active

2023-2671 HB1082 SD2 SMA.docx

medical cannabis permits shall be honored through their
 expiration date."

3 SECTION 3. Section 329-126, Hawaii Revised Statutes, is
4 amended to read as follows:

5 "§329-126 Protections afforded to a treating physician or 6 advanced practice registered nurse. (a) No physician or 7 advanced practice registered nurse shall be subject to arrest or 8 prosecution, penalized in any manner, or denied any right or 9 privilege for providing written certification for the medical 10 use of cannabis for a qualifying patient; provided that:

11 (1)The physician or advanced practice registered nurse 12 has diagnosed the patient as having a debilitating 13 medical condition, as defined in section 329-121; 14 The physician or advanced practice registered nurse (2) 15 has explained the potential risks and benefits of the 16 medical use of cannabis, as required under section 17 329-122;

18 (3) The written certification is based upon the
19 physician's or advanced practice registered nurse's
20 professional opinion after having completed a full
21 assessment of the patient's medical history and

2023-2671 HB1082 SD2 SMA.docx

H.B. NO. ¹⁰⁸² H.D. 3 S.D. 2

1	current medical condition made in the course of a
2	[bona fide] physician-patient relationship or [bona
3	fide] advanced practice registered nurse-patient
4	relationship, as applicable; and
5	(4) The physician or advanced practice registered nurse
6	has complied with the registration requirements of
7	section 329-123.
8	(b) For purposes of this section, a [bona fide] physician-
9	patient relationship may be established via telehealth, as
10	defined in section 453-1.3(j), and a [bona fide] advanced
11	practice registered nurse-patient relationship may be
12	established via telehealth, as defined in section 457-2;
13	provided that treatment recommendations that include certifying
14	a patient for the medical use of cannabis via telehealth shall
15	be allowed only after an initial in-person consultation between
16	the certifying physician or advanced practice registered nurse
17	and the patient."
18	SECTION 4. Section 329D-1, Hawaii Revised Statutes, is
19	amended as follows:
20	1. By adding a new definition to be appropriately inserted
21	and to read as follows:

2023-2671 HB1082 SD2 SMA.docx

1	""Waiting room" means a designated area at the public
2	entrance of a retail dispensing location that may be accessed by
3	a member of the general public who is waiting for, assisting, or
4	accompanying a qualifying patient, primary caregiver, qualifying
5	out-of-state patient, or caregiver of a qualifying out-of-state
6	patient who enters or remains on the premises of a retail
7	dispensing location for the purpose of a transaction conducted
8	pursuant to sections 329D-6 and 329D-13, provided that the
9	storage, display, and retail sale of cannabis and manufactured
10	cannabis products shall be prohibited within the waiting room
11	area."
12	2. By amending the definition of "manufactured cannabis
13	product" to read as follows:
14	""Manufactured cannabis product" means [any] <u>:</u>
15	(1) Any capsule, lozenge, oil or oil extract, tincture,
16	ointment or skin lotion, pill, transdermal patch, or
17	pre-filled and sealed container used to aerosolize and
18	deliver cannabis orally $[-7]$ or by inhalation, such as
19	an inhaler [or], nebulizer, <u>or device that provides</u>
20	safe pulmonary administration, that has been
21	manufactured using cannabis $[\tau]$:

2023-2671 HB1082 SD2 SMA.docx

Page 5

1	(2) Edible cannabis products;
2	(3) Pre-rolled cannabis flower products; or [any]
3	(4) Any other products as specified by the department
4	pursuant to section 329D-10(a)(11)."
5	SECTION 5. Section 329D-6, Hawaii Revised Statutes, is
6	amended by amending subsection (r) to read as follows:
7	"(r) The department may authorize a dispensary to purchase
8	cannabis and manufactured cannabis products from another
9	dispensary in a manner prescribed by the department by rules
10	adopted pursuant to [this chapter and chapter 91;] <u>section 329D-</u>
11	27; provided that:
12	(1) The purchasing dispensary establishes to the
13	department's satisfaction that:
14	(A) The purchase is necessary to ensure that
15	qualifying patients have continuous access to
16	cannabis for medical use; or
17	(B) The cannabis and manufactured cannabis products
18	are for medical, scientific, or other legitimate
19	purposes approved by the State;
20	(2) The selling dispensary may transport no more than
21	eight hundred ounces of cannabis or manufactured

2023-2671 HB1082 SD2 SMA.docx

	cannabis products to the purchasing dispensary within
	a thirty-day period[;] or other amounts with prior
	approval by the department;
(3)	The cannabis and manufactured cannabis products are
	transported between the dispensaries for medical,
	scientific, or other legitimate purposes approved by
	the State; and
(4)	Nothing in this subsection shall relieve any
	dispensary of its responsibilities and obligations
	under this chapter and chapter 329."
SECT	ION 6. Section 329D-7, Hawaii Revised Statutes, is
amended to	o read as follows:
"§32	9D-7 Medical cannabis dispensary rules. The
departmen	t shall establish standards with respect to:
(1)	The number of medical cannabis dispensaries that shall
	be permitted to operate in the State;
(2)	A fee structure for:
	(A) The submission of applications and renewals of
	licenses to dispensaries; provided that the
	department shall consider the market conditions
	<pre>(4) SECT amended to "\$32 departmen (1)</pre>

2023-2671 HB1082 SD2 SMA.docx

1			in each county in determining the license renewal
2			fee amounts;
3		(B)	The submission of applications for each
4			additional production center; and
5		(C)	Dispensary-to-dispensary sales authorized by
6			<pre>section 329D-6(r);</pre>
7	(3)	Crit	eria and procedures for the consideration and
8		sele	ction, based on merit, of applications for
9		lice	nsure of dispensaries; provided that the criteria
10		shal	l include but not be limited to an applicant's:
11		(A)	Ability to operate a business;
12		(B)	Financial stability and access to financial
13			resources; provided that applicants for medical
14			cannabis dispensary licenses shall provide
15			documentation that demonstrates control of not
16			less than \$1,000,000 in the form of escrow
17			accounts, letters of credit, surety bonds, bank
18			statements, lines of credit, or the equivalent to
19			begin operating the dispensary;
20		(C)	Ability to comply with the security requirements
21			developed pursuant to paragraph (6);



1		(D) Capacity to meet the needs of qualifying patients
2		and qualifying out-of-state patients;
3		(E) Ability to comply with criminal background check
4		requirements developed pursuant to paragraph (8);
5		and
6		(F) Ability to comply with inventory controls
7		developed pursuant to paragraph (13);
8	(4)	Specific requirements regarding annual audits and
9		reports required from each production center and
10		dispensary licensed pursuant to this chapter;
11	(5)	Procedures for announced and unannounced inspections
12		by the department or its agents of production centers
13		and dispensaries licensed pursuant to this chapter;
14		provided that inspections for license renewals shall
15		be unannounced;
16	(6)	Security requirements for the operation of production
17		centers and retail dispensing locations; provided
18		that, at a minimum, the following shall be required:
19		(A) For production centers:

2023-2671 HB1082 SD2 SMA.docx



1	(i)	Video monitoring and recording of the
2		premises; provided that recordings shall be
3		retained for fifty days;
4	(ii)	Fencing that surrounds the premises and that
5		is sufficient to reasonably deter intruders
6		and prevent anyone outside the premises from
7		viewing any cannabis in any form;
8	(iii)	An alarm system; and
9	(iv)	Other reasonable security measures to deter
10		or prevent intruders, as deemed necessary by
11		the department;
12	(B) For	retail dispensing locations:
13	(i)	Presentation of a valid government-issued
14		photo identification and a valid
15		identification as issued by the department
16		pursuant to section 329-123 by a qualifying
17		patient or caregiver, or section 329-123.5
18		by a qualifying out-of-state patient or
19		caregiver of a qualifying out-of-state
20		patient, upon entering the premises;

1		(ii) Video monitoring and recording of the
2		premises; provided that recording shall be
3		retained for fifty days;
4		(iii) An alarm system;
5		(iv) Exterior lighting; and
6		(v) Other reasonable security measures as deemed
7		necessary by the department;
8	(7)	Security requirements for the transportation of
9		cannabis and manufactured cannabis products between
10		production centers and retail dispensing locations and
11		between a production center, retail dispensing
12		location, qualifying patient, primary caregiver,
13		qualifying out-of-state patient, or caregiver of a
14		qualifying out-of-state patient and a certified
15		laboratory, pursuant to section 329-122(f);
16	(8)	Standards and criminal background checks to ensure the
17		reputable and responsible character and fitness of all
18		license applicants, licensees, employees,
19		subcontractors and their employees, and prospective
20		employees of medical cannabis dispensaries to operate
21		a dispensary; provided that the standards, at a

2023-2671 HB1082 SD2 SMA.docx

H.B. NO. ¹⁰⁸² H.D. 3 S.D. 2

1		minimum, shall exclude from licensure or employment
2		any person convicted of any felony;
3	(9)	The training and certification of operators and
4		employees of production centers and dispensaries;
5	(10)	The types of manufactured cannabis products that
6		dispensaries shall be authorized to manufacture and
7		sell pursuant to sections 329D-9 and 329D-10;
8	(11)	Laboratory standards related to testing cannabis and
9		manufactured cannabis products for content,
10		contamination, and consistency;
11	(12)	The quantities of cannabis and manufactured cannabis
12		products that a dispensary may sell or provide to a
13		qualifying patient, primary caregiver, qualifying out-
14		of-state patient, or caregiver of a qualifying out-of-
15		state patient; provided that no dispensary shall sell
16		or provide to a qualifying patient, primary caregiver,
17		qualifying out-of-state patient, or caregiver of a
18		qualifying out-of-state patient any combination of
19		cannabis and manufactured products that:

2023-2671 HB1082 SD2 SMA.docx



1		(A)	During a period of fifteen consecutive days,	
2			exceeds the equivalent of four ounces of	
3			cannabis; or	
4		(B)	During a period of thirty consecutive days,	
5			exceeds the equivalent of eight ounces of	
6			cannabis;	
7	(13)	Disp	ensary and production center inventory controls to	
8		prev	ent the unauthorized diversion of cannabis or	
9		manu	factured cannabis products or the distribution of	
10		cann	cannabis or manufactured cannabis products to a	
11		qualifying patient, primary caregiver, qualifying out-		
12		of-state patient, or caregiver of a qualifying out-of-		
13		state patient in quantities that exceed limits		
14		established by this chapter; provided that the		
15		cont	controls, at a minimum, shall include:	
16		(A)	A computer software tracking system as specified	
17			in section 329D-6(j) and (k); and	
18		(B)	Product packaging standards sufficient to allow	
19			law enforcement personnel to reasonably determine	
20			the contents of an unopened package;	

2023-2671 HB1082 SD2 SMA.docx

H.B. NO. ¹⁰⁸² H.D. 3 S.D. 2

1	(14)	Limitation to the size or format of signs placed
2		outside a retail dispensing location or production
3		center; provided that the signage limitations, at a
4		minimum, shall comply with section 329D-6(0)(2) and
5		shall not include the image of a cartoon character or
6		other design intended to appeal to children;
7	(15)	The disposal or destruction of unwanted or unused
8		cannabis and manufactured cannabis products;
9	(16)	The enforcement of the following prohibitions against:
10		(A) The sale or provision of cannabis or manufactured
11		cannabis products to unauthorized persons;
12		(B) The sale or provision of cannabis or manufactured
13		cannabis products to a qualifying patient,
14		primary caregiver, qualifying out-of-state
15		patient, or caregiver of a qualifying out-of-
16		state patient in quantities that exceed limits
17		established by this chapter;
18		(C) Any use or consumption of cannabis or
19		manufactured cannabis products on the premises of
20		a retail dispensing location or production
21		center; and

2023-2671 HB1082 SD2 SMA.docx



1		D) The distribution of cannabis or manufactured
2		cannabis products, for free, on the premises of a
3		retail dispensing location or production center;
4	(17)	he establishment of a range of penalties for
5		iolations of this chapter or rule adopted thereto;
6		and]
7	(18)	process to recognize and register patients who are
8		uthorized to purchase, possess, and use medical
9		annabis in another state, a United States territory,
10		r the District of Columbia as qualifying out-of-state
11		atients; provided that this registration process may
12		ommence no sooner than January 1, 2018[-]; and
13	(19)	ecurity requirements and restrictions regarding
14		aiting rooms, including but not limited to:
15		A) Security measures to prevent unauthorized access
16		to any area within the retail dispensing location
17		outside of the waiting room;
18		B) Restrictions on marketing and advertising within
19		the waiting room;
20		C) Restrictions on signage within the waiting room;
21		and

2023-2671 HB1082 SD2 SMA.docx



1		(D) Other reasonable security measures or
2		restrictions as deemed necessary by the
3		department."
4	SECTI	ION 7. Section 329D-10, Hawaii Revised Statutes, is
5	amended by	amending subsection (a) to read as follows:
6	"(a)	The types of medical cannabis products that may be
7	manufactur	red and distributed pursuant to this chapter shall be
8	limited to	:
9	(1)	Capsules;
10	(2)	Lozenges;
11	(3)	Pills;
12	(4)	Oils and oil extracts;
13	(5)	Tinctures;
14	(6)	Ointments and skin lotions;
15	(7)	Transdermal patches;
16	(8)	Pre-filled and sealed containers used to aerosolize
17		and deliver cannabis orally $[-7]$ or by inhalation, such
18		as [with] an inhaler [or] <u>,</u> nebulizer[;] <u>, or device</u>
19		that provides safe pulmonary administration; provided
20		that [containers]:

2023-2671 HB1082 SD2 SMA.docx

1	<u>(A)</u>	Containers need not be manufactured by the
2		licensed dispensary but shall be filled with
3		cannabis, cannabis oils, or cannabis extracts
4		manufactured by the licensed dispensary[$_{+}$] or
5		purchased from another dispensary pursuant to
6		section 329D-6(r); but shall not contain
7		nicotine, tobacco-related products, or any other
8		non-cannabis derived products; and [shall be
9		designed to be used with devices used to provide
10		safe pulmonary administration of manufactured
11		cannabis-products;
12	(9) Devi	ees]
13	<u>(B)</u>	For devices that provide safe pulmonary
14		administration[; provided that]:
15	[(A)]	(i) The heating element of the device, if any,
16		[is] <u>shall be</u> made of inert materials such as
17		glass, ceramic, or stainless steel, and not of
18		plastic or rubber;
		(ii) The device [is] shall be distributed solely
19		<u>(11)</u> The device [15] <u>shart be</u> discributed solery

2023-2671 HB1082 SD2 SMA.docx

1		resistant, sealed containers that do not contain
2		nicotine or other tobacco products;
3	[-(C)-	The device is used to acrosolize and deliver
4		cannabis by inhalation, such as an inhaler,
5		medical-grade nebulizer, or other similar medical
6		grade volitization device;
7	(D)]	(iii) There [is] <u>shall be</u> a temperature control
8		on the device that is regulated to prevent the
9		combustion of cannabis oil; and
10	[(E)]	(iv) The device need not be manufactured by the
11		licensed dispensary;
12	(9) Pre-	rolled cannabis flower products, as specified by
13	the	department;
14	(10) [Oth	e r products, including edible] <u>Edible</u> cannabis
15	prod	ucts, as specified by the department; and
16	(11) Othe	r products as specified by the department."
17	SECTION 8	. Section 329D-15, Hawaii Revised Statutes, is
18	amended by ame	nding subsection (a) to read as follows:
19	"(a) No	person shall intentionally or knowingly enter or
20	remain upon th	e premises of a medical cannabis retail dispensing
21	location unles	s the individual is:

2023-2671 HB1082 SD2 SMA.docx

H.B. NO. ¹⁰⁸² H.D. 3 S.D. 2

1	(1)	An individual licensee or registered employee of the
2		dispensary;
3	(2)	A qualifying patient, primary caregiver, qualifying
4		out-of-state patient, or caregiver of a qualifying
5		out-of-state patient;
6	(3)	A government employee or official acting in the
7		person's official capacity; or
8	(4)	Previously included on a current department-approved
9		list provided to the department by the licensee of
10		those persons who are allowed into that dispensary's
11		facilities for a specific purpose for that dispensary,
12		including but not limited to construction,
13		maintenance, repairs, legal counsel, providers of
14		paratransit or other assistive services required by a
15		qualifying patient, primary caregiver, qualifying out-
16		of-state patient, or caregiver of a qualifying out-of-
17		state patient to access a retail dispensary location,
18		or investors; provided that;
19		(A) The person has been individually approved by the
20		department to be included on the list;

1	(B)	The person is at least twenty-one years of age,
2		as verified by a valid government issued
3		identification card;
4	(C)	The department has confirmed that the person has
5		no felony convictions;
6	(D)	The person is escorted by an individual licensee
7		or registered employee of the dispensary at all
8		times while in the dispensary facility;
9	(E)	The person is only permitted within those
10		portions of the dispensary facility as necessary
11		to fulfill the person's purpose for entering;
12	(F)	The person is only permitted within the
13		dispensary facility during the times and for the
14		duration necessary to fulfill the person's
15		purpose for entering;
16	(G)	The dispensary shall keep an accurate record of
17		each person's first and last name, date and times
18		upon entering and exiting the dispensary
19		facility, purpose for entering, and the identity
20		of the escort; and

2023-2671 HB1082 SD2 SMA.docx



1	(H) The approved list shall be effective for one year
2	from the date of the department approval[+];
3	provided that a member of the general public may enter or remain
4	within the waiting room of a retail dispensing location."
5	SECTION 9. Section 329D-21, Hawaii Revised Statutes, is
6	amended by amending subsection (b) to read as follows:
7	"(b) Any person who violates any of the provisions of this
8	chapter or the rules adopted pursuant thereto shall be fined not
9	less than \$100 nor more than \$1,000 for each [violation.]
10	separate violation. Each day on which a violation occurs or
11	continues shall be counted as a separate violation."
12	SECTION 10. Section 329D-26, Hawaii Revised Statutes, is
13	amended to read as follows:
14	"[{]§329D-26[]] Public education. [(a) The department]
15	Medical cannabis dispensaries, in conjunction with physicians
16	and advanced practice registered nurses who issue written
17	certifications pursuant to section 329-123, shall conduct a
18	continuing education and training program to explain and clarify
19	the purposes and requirements of this chapter or to provide
20	substance abuse prevention and education. The program shall
21	target community partner agencies, physicians and other health

2023-2671 HB1082 SD2 SMA.docx



1	care providers, patients and caregivers, law enforcement	
2	agencies, law and policy makers, and the general public.	
3	[{b}The department shall employ at least one full-time	
4	staff member whose qualifications and duties include the	
5	provision of medical cannabis health education.]"	
6	SECTION 11. (a) The office of medical cannabis control	
7	and regulation, in collaboration with the chairpersons of the	
8	senate committee on health and human services and the house of	
9	representatives committee on health and homelessness, shall	
10	convene a medical and adult use of cannabis working group to	
11	research, develop, and finalize recommendations for the creation	
12	of a dual use regulatory system allowing access to medical	
13	cannabis and cannabis for adult use.	
14	(b) The medical and adult use of cannabis working group	
15	shall include the following:	
16	(1) The chairperson of the senate committee on health and	
17	human services, or the chairperson's designee;	
18	(2) The chairperson of the house of representatives	
19	committee on health and homelessness, or the	
20	chairperson's designee;	

2023-2671 HB1082 SD2 SMA.docx



1	(3)	The chairperson of the senate committee on agriculture
2		and environment, or the chairperson's designee;
3	(4)	The chairperson of the house of representatives
4		committee on agriculture and food systems, or the
5		chairperson's designee;
6	(5)	The attorney general, or the attorney general's
7		designee;
8	(6)	The director of health, or the director's designee;
9	(7)	The chairperson of the board of agriculture, or the
10		chairperson's designee;
11	(8)	The director of taxation, or the director's designee;
12	(9)	The prosecuting attorney of the city and county of
13		Honolulu, or the prosecuting attorney's designee;
14	(10)	A police chief chosen by the Law Enforcement and
15		Security Coalition of Hawaii, or the police chief's
16		designee;
17	(11)	A representative of the Drug Policy Forum of Hawaii;
18	(12)	A representative from the Coalition for a Drug-Free
19		Hawaii;
20	(13)	Four participants in Hawaii's medical marijuana
21		program, one of whom is a patient over the age of



H.B. NO. ¹⁰⁸² H.D. 3 S.D. 2

1 eighteen, one of whom is a patient or guardian of a patient who is under the age of ten, one of whom is a 2 named careqiver of a patient, and one of whom is a 3 representative of a licensed dispensary; and 4 5 (14) Any other participants identified in consultation with the office of medical cannabis control and regulation, 6 and the chairpersons of the senate committee on health 7 and human services and the house of representatives 8 9 committee on health and homelessness. 10 The medical and adult use of cannabis working group (C) 11 shall submit a report of its findings and recommendations,

12 including any proposed legislation, to the legislature no later 13 than ten days prior to the convening of the regular session of 14 2024.

15 SECTION 12. Statutory material to be repealed is bracketed16 and stricken. New statutory material is underscored.

17 SECTION 13. This Act shall take effect on June 30, 2050.



Report Title:

Medical Cannabis Dispensary System; Physician-Patient Relationship; Advanced Practice Registered Nurse-Patient Relationship; Written Certification; Waiting room; Violations; Continuing Education; Working Group

Description:

Requires that written certifications for a patient with a chronic condition be valid for three years. Removes the requirement that a certifying physician or advanced practice registered nurse have a "bona fide" physician-patient or advanced practice registered nurse-patient relationship to certify that a patient has a debilitating medical condition pursuant to chapter 329, Hawaii Revised Statutes. Amends the definition of "manufactured cannabis product" to include devices that provides safe pulmonary administration, edible cannabis products, and pre-rolled cannabis flower products. Defines "waiting room" within a medical cannabis retail dispensary. Allows primary caregivers, qualifying out-of-state patients, and caregivers of a qualifying out-of-state patient to access the waiting room. Allows selling dispensaries to transport not more than eight hundred ounces of cannabis or manufactured cannabis products to purchasing dispensaries within a thirty-day period, or other amounts with prior approval of the Department of Health. Clarifies the types of medical cannabis products that may be manufactured and distributed pursuant to the State's medical cannabis dispensary system. Clarifies that each day of a violation of chapter 329D, Hawaii Revised Statutes, is a separate violation. Amends the rule-making authority for dispensary-to-dispensary sales. Requires medical cannabis dispensaries, in conjunction with physicians and advanced practice registered nurses who issue written certifications pursuant to section 329-123, Hawaii Revised Statutes, to conduct the continuing education and training program required by section 329D-26, Hawaii Revised Statutes, rather than the Department of Health. Establishes a Medical and Adult Use of Cannabis Working Group. Effective 6/30/2050. (SD2)

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.

